Beta-D-Xylofuranose

Quantitative determination of azacitidine triphosphate in peripheral blood mononuclear cells using liquid chromatography coupled with high-resolution mass spectrometry
Ellen J.B. Derissena,∗, Michel J.X. Hillebranda, Hilde Rosinga, Hans M.M.B. Ottenb, Eric Laillec, Jan H.M. Schellens d,e, Jos H. Beijnena
Journal of Pharmaceutical and Biomedical Analysis 90 (2014) 7–14
The Development and Manufacture of Azacitidine, Decitabine, and Cladribine: Stereoselective Ribonucleoside Drug Synthesis Using the Vorbrüggen Glycosylation
Erick W. Co and Julian P. Henschke
Comprehensive Accounts of Pharmaceutical Research and Development: From Discovery to Late-Stage Process Development Volume 2 (pp.271-321)Chapter: 9
DEVELOPMENT AND VALIDATION OF STABILITY-INDICATING RP-HPLC ASSAY METHOD FOR AZACITIDINE AND ITS BULK DRUG
Brahmaiah Marineni, T Sreenivasulu Reddy
Int J Pharm Pharm Sci, Vol 6, Issue 8, 240-244Original Article 
A Novel RP-HPLC Method for the Quantification of Azacitidine and Its Impurities in Active Pharmaceutical Ingredients and Pharmaceutical Dosage Forms
Arun Kumar Kuna*, Seru Ganapaty, G. V. Radha
Int. J. Pharm. Sci. Rev. Res., 54(1), January - February 2019; Article No. 03, Pages: 16-22

Beta-D-Xylofuranose is chemically (2R,3R,4R,5R)-5-(hydroxymethyl)tetrahydrofuran-2,3,4-triol. Beta-D-Xylofuranose is supplied with detailed characterization data compliant with regulatory guideline. Beta-D-Xylofuranose can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Azacitidine.

The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.